Aroa Biosurgery (ARX) AGM 2025 summary

Opening remarks and agenda

• Board and executive team introduced, including key committee chairs and company secretaries.

• Agenda included remarks from the chair, CEO presentation, Q&A, financial statement consideration, and voting on resolutions.

Board and executive committee updates

• Board comprises experienced professionals in healthcare, commercial, operational, and financial sectors.

• Board composition and committee leadership roles highlighted, including audit, remuneration, and risk committees.

• Joint company secretaries and CFO roles highlighted.

Financial performance review

• FY25 total revenue reached NZ$84.7m, a 23% increase year-over-year.

• Myriad product revenue grew 38% to NZ$32.2m, with manufacturing margins and product gross margin at 86%.

• Normalised EBITDA improved to NZ$4.2m, up 235% from the previous year.

• Three consecutive quarters of positive operating cash flow recorded, with direct sales now over half of total sales.

• FY26 guidance projects NZ$92–$100m revenue and NZ$5–$8m normalised EBITDA.